Cargando…

Therapeutic Assessment of Chloroquine-Primaquine Combined Regimen in Adult Cohort of Plasmodium vivax Malaria from Primary Care Centres in Southwestern India

BACKGROUND: Several reports of chloroquine treatment failure and resistance in Plasmodium vivax malaria from Southeast Asian countries have been published. Present study was undertaken to assess the efficacy of chloroquine-primaquine (CQ-PQ) combined regimen for the treatment of P. vivax malaria pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Saravu, Kavitha, Kumar, Rishikesh, Ashok, Herikudru, Kundapura, Premananda, Kamath, Veena, Kamath, Asha, Mukhopadhyay, Chiranjay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912090/
https://www.ncbi.nlm.nih.gov/pubmed/27315280
http://dx.doi.org/10.1371/journal.pone.0157666
_version_ 1782438216517812224
author Saravu, Kavitha
Kumar, Rishikesh
Ashok, Herikudru
Kundapura, Premananda
Kamath, Veena
Kamath, Asha
Mukhopadhyay, Chiranjay
author_facet Saravu, Kavitha
Kumar, Rishikesh
Ashok, Herikudru
Kundapura, Premananda
Kamath, Veena
Kamath, Asha
Mukhopadhyay, Chiranjay
author_sort Saravu, Kavitha
collection PubMed
description BACKGROUND: Several reports of chloroquine treatment failure and resistance in Plasmodium vivax malaria from Southeast Asian countries have been published. Present study was undertaken to assess the efficacy of chloroquine-primaquine (CQ-PQ) combined regimen for the treatment of P. vivax malaria patients who were catered by the selected primary health centres (PHCs) of Udupi taluk, Udupi district, Karnataka, India. METHOD: Five PHCs were selected within Udupi taluk based on probability proportional to size. In-vivo therapeutic efficacy assessment of CQ (1500 mg over three days) plus PQ (210 mg over 14 days) regimen was carried out in accordance with the World Health Organization’s protocol of 28 days follow-up among microscopically diagnosed monoinfection P. vivax cohort. RESULTS: In total, 161 participants were recruited in the study of which, 155 (96.3%) participants completed till day 28 follow-up, fully complied with the treatment regimen and showed adequate clinical and parasitological response. Loss to follow up was noted with 5 (3.1%) participants and non-compliance with treatment regimen occurred with one participant (0.6%). Glucose-6-phosphate dehydrogenase deficiency (G6PDd, <30% of normal mean activity) was noted among 5 (3.1%) participants and one of them did develop PQ induced dark-brown urination which subsided after PQ discontinuation. G6PDd patients were treated with PQ 45 mg/week for eight weeks while PQ was discontinued in one case with G6PD 1.4 U/g Hb due to complaint of reddish-brown coloured urine by 48 hours of PQ initiation. Nested polymerase chain reaction test revealed 45 (28%) cases as mixed (vivax and falciparum) malaria. CONCLUSIONS: The CQ-PQ combined regimen remains outstandingly effective to treat uncomplicated P. vivax malaria in Udupi taluk and thus it should continue as first line regimen. For all P. vivax cases, G6PD screening before PQ administration must be mandatory and made available in all PHCs.
format Online
Article
Text
id pubmed-4912090
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-49120902016-07-06 Therapeutic Assessment of Chloroquine-Primaquine Combined Regimen in Adult Cohort of Plasmodium vivax Malaria from Primary Care Centres in Southwestern India Saravu, Kavitha Kumar, Rishikesh Ashok, Herikudru Kundapura, Premananda Kamath, Veena Kamath, Asha Mukhopadhyay, Chiranjay PLoS One Research Article BACKGROUND: Several reports of chloroquine treatment failure and resistance in Plasmodium vivax malaria from Southeast Asian countries have been published. Present study was undertaken to assess the efficacy of chloroquine-primaquine (CQ-PQ) combined regimen for the treatment of P. vivax malaria patients who were catered by the selected primary health centres (PHCs) of Udupi taluk, Udupi district, Karnataka, India. METHOD: Five PHCs were selected within Udupi taluk based on probability proportional to size. In-vivo therapeutic efficacy assessment of CQ (1500 mg over three days) plus PQ (210 mg over 14 days) regimen was carried out in accordance with the World Health Organization’s protocol of 28 days follow-up among microscopically diagnosed monoinfection P. vivax cohort. RESULTS: In total, 161 participants were recruited in the study of which, 155 (96.3%) participants completed till day 28 follow-up, fully complied with the treatment regimen and showed adequate clinical and parasitological response. Loss to follow up was noted with 5 (3.1%) participants and non-compliance with treatment regimen occurred with one participant (0.6%). Glucose-6-phosphate dehydrogenase deficiency (G6PDd, <30% of normal mean activity) was noted among 5 (3.1%) participants and one of them did develop PQ induced dark-brown urination which subsided after PQ discontinuation. G6PDd patients were treated with PQ 45 mg/week for eight weeks while PQ was discontinued in one case with G6PD 1.4 U/g Hb due to complaint of reddish-brown coloured urine by 48 hours of PQ initiation. Nested polymerase chain reaction test revealed 45 (28%) cases as mixed (vivax and falciparum) malaria. CONCLUSIONS: The CQ-PQ combined regimen remains outstandingly effective to treat uncomplicated P. vivax malaria in Udupi taluk and thus it should continue as first line regimen. For all P. vivax cases, G6PD screening before PQ administration must be mandatory and made available in all PHCs. Public Library of Science 2016-06-17 /pmc/articles/PMC4912090/ /pubmed/27315280 http://dx.doi.org/10.1371/journal.pone.0157666 Text en © 2016 Saravu et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Saravu, Kavitha
Kumar, Rishikesh
Ashok, Herikudru
Kundapura, Premananda
Kamath, Veena
Kamath, Asha
Mukhopadhyay, Chiranjay
Therapeutic Assessment of Chloroquine-Primaquine Combined Regimen in Adult Cohort of Plasmodium vivax Malaria from Primary Care Centres in Southwestern India
title Therapeutic Assessment of Chloroquine-Primaquine Combined Regimen in Adult Cohort of Plasmodium vivax Malaria from Primary Care Centres in Southwestern India
title_full Therapeutic Assessment of Chloroquine-Primaquine Combined Regimen in Adult Cohort of Plasmodium vivax Malaria from Primary Care Centres in Southwestern India
title_fullStr Therapeutic Assessment of Chloroquine-Primaquine Combined Regimen in Adult Cohort of Plasmodium vivax Malaria from Primary Care Centres in Southwestern India
title_full_unstemmed Therapeutic Assessment of Chloroquine-Primaquine Combined Regimen in Adult Cohort of Plasmodium vivax Malaria from Primary Care Centres in Southwestern India
title_short Therapeutic Assessment of Chloroquine-Primaquine Combined Regimen in Adult Cohort of Plasmodium vivax Malaria from Primary Care Centres in Southwestern India
title_sort therapeutic assessment of chloroquine-primaquine combined regimen in adult cohort of plasmodium vivax malaria from primary care centres in southwestern india
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912090/
https://www.ncbi.nlm.nih.gov/pubmed/27315280
http://dx.doi.org/10.1371/journal.pone.0157666
work_keys_str_mv AT saravukavitha therapeuticassessmentofchloroquineprimaquinecombinedregimeninadultcohortofplasmodiumvivaxmalariafromprimarycarecentresinsouthwesternindia
AT kumarrishikesh therapeuticassessmentofchloroquineprimaquinecombinedregimeninadultcohortofplasmodiumvivaxmalariafromprimarycarecentresinsouthwesternindia
AT ashokherikudru therapeuticassessmentofchloroquineprimaquinecombinedregimeninadultcohortofplasmodiumvivaxmalariafromprimarycarecentresinsouthwesternindia
AT kundapurapremananda therapeuticassessmentofchloroquineprimaquinecombinedregimeninadultcohortofplasmodiumvivaxmalariafromprimarycarecentresinsouthwesternindia
AT kamathveena therapeuticassessmentofchloroquineprimaquinecombinedregimeninadultcohortofplasmodiumvivaxmalariafromprimarycarecentresinsouthwesternindia
AT kamathasha therapeuticassessmentofchloroquineprimaquinecombinedregimeninadultcohortofplasmodiumvivaxmalariafromprimarycarecentresinsouthwesternindia
AT mukhopadhyaychiranjay therapeuticassessmentofchloroquineprimaquinecombinedregimeninadultcohortofplasmodiumvivaxmalariafromprimarycarecentresinsouthwesternindia